Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recce Pharmaceuticals (OP:RECEF)

0.2200 UNCHANGED
Last Price Updated: 9:33 AM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recce Pharmaceuticals

Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) managing director and CEO James Graham talks with Proactive’s Jonathan Jackson about how Recce has administered the first doses in the latest cohort of... 
Via TheNewswire.com
News headline image
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial 
Via News Direct
Recce Pharma welcomes approval for faster RECCE327 infusion rate
--News Direct-- 
Via News Direct
Recce Pharma welcomes approval for faster RECCE327 infusion rate
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham tells Proactive the company has been given the green light by an independent safety committee for the next cohort dosing of RECCE® 327... 
Via TheNewswire.com
Recce Pharma says commercial potential of its anti-infectives is gaining recognition
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive soon after announcing the company has raised a total of around $11 million across its recent placement, entitlement... 
Via TheNewswire.com
Recce Pharma says commercial potential of its anti-infectives is gaining recognition
--News Direct-- 
Via News Direct
Recce Pharma begins dosing in diabetic foot infection trial
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham tells Proactive the company has dosed patients in a Phase I/II diabetic foot infection (DFI) clinical trial, testing the safety and... 
Via TheNewswire.com
Recce Pharma begins dosing in diabetic foot infection trial
--News Direct-- 
Via News Direct
Recce Pharmaceuticals provides new hope in fight against superbugs
--News Direct-- 
Via News Direct
Recce Pharmaceuticals provides new hope in fight against superbugs
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive after welcoming positive clinical responses to a new gel formulation of its R327® drug candidate, covered by the... 
Via TheNewswire.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.